Form 4 for DGX Quest Diagnostics
Accepted 2024-07-26 00:00:00 ET · period of report 2024-07-24 · accession 0001022079-24-000168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-26 | 2024-07-24 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | S - Sale | $143.08 | -420 | 5,019 | -8% | -$60.1K | |
| 2024-07-26 | 2024-07-22 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $146.98 | +6 | 5,439 | +0.1% | +$881.88 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-24 | S | D | 420 | $143.08 | 5,019 | D | — | — | |
| 2 | Common | Common Stock | 2024-07-22 | L | A | 6 | $146.98 | 5,439 | D | — | — | (F1) Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. |